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ABSTRACT 
Aquilaria subintegra locally known as “Gaharu” belongs to the Thymelaeceae family. Its 
leaves have been claimed by Malay traditional practitioner in Malaysia were effective for 
the treatment of Alzheimer’s disease (AD). However, there is no scientific evidence 
available to support these claims. The AD is one of the most common neurodegenerative 
disorders and it causes dementia with aging. The acetylcholesterase (AChE) inhibitors were 
used for the treatment of AD. In this research the leaves and stem chloroform extract of A. 
subintegra were tested for AChE inhibitory activity. The TLC results of the leaves and 
stem of A. subintegra showed the presence of phenols, flavonoids, terpenoids, and alkaloids 
compounds in the extracts. The total phenol contents in the leaves and stem chloroform 
extracts were 164mgGAE/g and 210mgGAE/g respectively. Whereas, the total flavonoids 
contents in leaves and stem chloroform extracts were 414mgQE/g and 645mgQE/g 
respectively. The analysis of the stem chloroform extracts with LCMS/MS displayed that it 
contain kaempferol 3,4,7-trimethyl ether. The AChE inhibitory activity of leaves, stem 
chloroform extracts and kaempferol were 80%, 93% and 85.8% respectively. Brine Shrimp 
Lethality Assay (BSLA) exhibited LC50=11.64µg/ml of leaves chloroform extract, 
LC50=3.11µg/ml of stem chloroform extract, and LC50=9.59µg/ml for kaempferol. The 
response of leaves, stem chloroform extracts and kaempferol were perceived in Radial Arm 
Maze (RAM) through oral gavage to ICR male and female mice with impaired memory by 
valium. Administration of kaempferol to the mice significantly reduced the number of 
repeated entries to arms of maze in male and females rats. In conclusion, it could be 
postulated that the inhibition of AChE by leaves and stem chloroform extracts of A. 
subintegra could be due to the presence of kaempferol. Thus, it is safe to be used as a 
natural AChE inhibitor instead of berberine for the treatment of AD.  
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ABSTRAK 
Aquilaria subintegra dikenali sebagai "Gaharu" adalah dari keluarga Thymelaeceae. 
Daunnya telah didakwa oleh pengamal tradisional Melayu di Malaysia berkesan untuk 
rawatan penyakit Alzheimer (AD). Walau bagaimanapun, tiada bukti saintifik yang 
menyokong dakwaan itu. AD adalah salah satu penyakit neurodegenaratif yang paling biasa 
dan ia menyebabkan demensia dengan penuaan. Perancat Acetylcholesterase (AChE) telah 
digunakan untuk rawatan AD. Dalam kajian ini ekstrak batang dan daun kloroform telah 
diuji untuk aktiviti perencatan AChE. Keputusan dari ekstrak TLC daun dan batang A. 
subintegra menunjukkan kehadiran sebatan fenol, flavonoid, terpenoid dan alkaloid. 
Jumlah kandungan fenol dalam ekstrak daun dan ekstrak batang adalah 164 mgGAE/g dan 
210 mgGAE/g masing-masing. Manakala, jumlah kandungan flavonoid dalam ekstrak daun 
dan ekstrak batang adalah 414 mgQE /g dan 645 mgQE/g masing-masing. Analisis ekstrak 
batang dengan LCMS/MS memaparkan bahawa ia mengandungi kaempferol 3,4,7-
trimethyl eter. Aktiviti perencatan AChE daripada ekstrak daun, batang dan kaempferol 
adalah 80%, 93% dan 85.8% masing-masing BSLA memberikan nilai LC50 = 11.64 μg/ml 
bagi ekstrak daun, LC50 = 3.11 μg/ml bagi ekstrak batang, dan LC50 = 9.59 μg/ml bagi 
kaempferol. Kesan ekstrak daun, batang dan kaempferol diperhatikan dalam kajian RAM 
(lengan radial maze) secasa oral gavage pada tikus jantan dan betina ICR dengan dengan 
menjejaskan ingatan menggunakan valium. Penganbilan kaempferol pada tikus 
mengurangkan dengan signifikan bilangan entri berulang ke RAM maze dalam tikus jantan 
dan betina. Kesimpulannya, maka boleh dipostilasikan bahawa perencatan AChE oleh 
ekstrak daun dan batang A. subintegra adalah disebabkan kehadiran kaempferol dan dengan 
itu ia boleh digunakan sebagai perencat AChE semulajadi selain daripada berberine untuk 
rawatan AD.  
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CHAPTER 1 INTRODUCTION 
 
AD is one of the most common neurodegenerative disorders that cause dementia 
with aging. Brookmeyer et al. (2007) predicted that AD would affect 1 in 85 people 
globally by 2050. The AChE inhibitors are chemical agents used for symptomatic treatment 
of AD. AChE could hydrolyze the neurotransmitter acetylcholine due to its protease 
activity. Golan et al. (2011) declared that AChE has high catalytic activity and it is able to 
hydrolyze 4×105 molecules of acetylcholine in one minute. The most common view in the 
treatment of AD is the effectiveness of AChE inhibitors to increase acetylcholine medicated 
neuron to neuron transmission. However, Tabet (2006) broadcasted that AChE inhibitors 
could have anti-inflammatory role by protecting cells from free radical toxicity and amyloid 
beta peptide injury. In 1999, McGleenon et al. proposed that Aβ and abnormal tau protein 
could be main factors in the development of AD. The influence of hyperphosphorylated tau 
protein on the expression of AChE was observed in another study by Garcia-Ayllon et al. 
(2011). They also found out the important role of AChE in AD by decreasing acetylcholine. 
Later, Anand et al. (2012) reported the activity of AChE inhibitors in AD management 
through decreasing Amyloid beta (Aβ) production and aggregation, or by increasing the 
removal of Aβ.  
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Aquilaria subintegra is locally known as “Gaharu”, is a plant which belongs to 
Thymelaeceae family. Recently, Malays traditional practitioners claim that A. subintegra 
leaves are effective for the treatment of AD. In South-East Asians traditional medicine the 
usage of agarwood was as a component in Kampo-formulae, such as ‘kiogan’ and 
‘rokushingan,’ for making sedatives. However, there is no scientific evidence available to 
support these claimed effects. Ueda et al. (2006) considered that the effects of agarwood 
(Aquilaria) as a traditional sedative, is due to its induction effects on central nervous 
system. Additionally, their study in rat cultured neuronal cells displayed that a new 
compound (4R, 5R, 7R)-1(10)-spirovetiven-11-o1-2-one and a 2-(2-phenylethyl) chromone 
derivative which were isolated from methanol extract of agarwood had significant 
succession effect on mRNA expression of brain derived neurotrophic factor (BDNF).  
Furthermore, some studies approved presence of natural AChE inhibitors in other plants. 
Yang et al. (2011) reported strong AChE inhibitory activity of an alkaloid skimminaine 
extracted from Zanthoxylum nitidum roots. They indicated that the anti-AChE activity of 
skimmianine may be impressive in the treatment of AD. In 2010, Pereira et al. found out 
that water extract of alkaloids from leaves of Catharanthus roseus strongly inhibited 
AChE.  
It was suggested by Kim et al. (2004) that kaempferol has anti-inflammatory 
properties like other flavonoids. Likewise, Serhan et al. (2008) illustrated that chronic 
inflammation occurs when acute inflammation is not resolved. Kaempferol has a 
detrimental effect in numerous disease including atherosclerosis, cancer, asthma, and some 
neurological disorders, such as AD. In 2012 Song et al. demonstrated that the kaempferol 
isolated from butterbur (Petasites japonicas) leaves might prevent the effects of Aβ that can 
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cause AD by inducing neurotoxicity and by producing free radicals that lead to cellular 
death.  
Using animal (ICR mice) might be beneficial to improve AChE inhibitors in 
treatment of AD. Dong et al. (2005) investigated two AChE inhibitors physostigmine and 
donepezil on memory related behaviors of mice. They suggested that AChE inhibitors 
could improve memory deficits in mice. Ikarashi et al. (2004) examined mice memory 
disturbance by measuring AChE concentrations in their brains. They found out that 
memory impairment in cholinergic system of the mice is due to Aβ accumulation which 
happens when AChE increased. Figueiró et al. (2010) extracted AChE inhibitors from 
Ptychopetalum olacoides and orally administrate these compounds to the mice. They 
improved meaningful AChE inhibitor activity of these extracts for treating 
neurodegenerative conditions which is useful for AD treatment. The Radial Arm Maze 
(RAM) is a practicable memory testing for displaying the effect of drugs. Foti et al. (2011) 
considered that the RAM can be analyzed via movement most aspects of the spatial 
function, as the analytical memory and the appropriate working memory. 
In this study the determination AChE of inhibitory activity of the chloroform leaves 
and stem extract of A. subintegra were evaluated in enzymatic bioassay system. The AChE 
inhibitory activity of the leaves, stem extracts and kaempferol detected in the stem 
chloroform extract of A. subintegra, was determined using Radial Arm Maze (RAM) 
through oral gavage to the ICR male and female mice with impaired memory by valium.   
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CHAPTER 2 LITRETURE REVIEW 
2.1 Plant studied-Aquilaria subintegra 
2.1.1 Scientific classification of Aquilaria subintegra 
Kingdom : Plantae 
Subkingdom : Angiosperms 
Division : Eudicots 
Class : Rosids 
Subclass : Malvales 
Order : Thymelaeaceae 
Family : Thymelaeaceae 
Genus : Aquilaria 
Species : Subintegra 
  
 
Figure 2.1: Aquilaria Subintegra 
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2.1.2 Scientific and common names 
Aquilaria subintegra is a species of plant in the family of Thymelaeaceae. Common 
names: agarwood, aloeswood, eaglewood. Vernacular names: Alas, Calambac, Ching karas, 
Gaharu, Galoop, Garu, Gharu, Karas, Kayu gaharu, Kekaras, Kepang, Laroo, Mengkaras, 
Ngalas, Sigi-sigi, Tabak, Taras gharu, Tengkaras. 
 
2.1.3 Distribution 
The phytogeographical region for Aquilaria subintegra comprises India, Burma, 
Thailand, Peninsular Malaysia, Sumatra, Borneo (Sabah, East-Kalimantan) and Philippines. 
 
2.1.4 Description 
Aquilaria subintegra is a tree that grows 6 to 20 m tall, its bole up to 60 cm in 
diameter, consistently straight however sometimes fluted. The buttresses are up to 2 m 
high. The bark is plane and whitish. The branchlets protected with the soft short hairs, they 
are slender and pale brown.  
The leaves of Aquilaria subintegra fortified by 4 to 6 mm long stalk, they are 
simple and arranged alternate. The area of the blade is between 7.5-12 × 2.5-5.5 cm, it 
shaped elliptical oblong to oblong lance. Generally the leaves are hairless but sometimes 
covered by soft short hairs. They are shiny on both surfaces. The apex is acuminate with 
acumen up to 2 cm long with rather aberrant veins in 12 to 16 pairs. Their bases are acute, 
attenuate or obtuse. The veins are distributed plane or obscure on the top surface and 
curving upward to the margin of leaves (Chua, 2008).  
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Aquilaria subintegra has terminal inflorescence, which is arising from axils, 
consistently from two nodes umbel. Each umbel has 10 flowers uphold by 5 to 15 mm long 
stalk. The pedicel is 3 to 6 mm long and slender. The flowers of this tree have 5 merous 
with the shape like a bell, 5 to 6 mm long and the soft short hairs on its outside. The color 
of the flowers is green or dirty yellow (Chua, 2008). 
The fruit of Aquilaria subintegra is a dorsal suture capsule, it has reverse egg 
shaped. It is protected with the soft short hairs. The fruit size is 3-4 cm × 2.5 cm. The seed 
of this tree has red hair. The seed size is 10 mm × 6 mm (Chua, 2008). 
 
2.1.5 Medicinal and other uses of Aquilaria subintegra 
The first appearance of Aquilaria plant was appreciated in the ceremonies of 
Buddhism or Islam since early ages, due to its ethereal pleasant scent. In South-East Asians 
traditional medicine the usage of agarwood was as a component in Kampo-formulae, such 
as ‘kiogan’ and ‘rokushingan,’ for making sedatives.  
Ueda et al. (2006) declared that agarwood extract could be effective on central 
nervous system (CNS) for instance it leads to excessive brain function. Additionally, their 
study in rat cultured neuronal cells displayed that a new compound (4R, 5R, 7R)-1(10)-
spirovetiven-11-o1-2-one and a 2-(2-phenylethyl) chromone derivative which were isolated 
from methanol extract of agarwood had significant succession effect on mRNA expression 
of brain derived neurotrophic factor (BDNF).  
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2.2 Flavonoids 
2.2.1 Introduction 
One of the largest groups of secondary metabolites which is extensively scattered in 
plant kingdom are flavonoids. More than 4000 structurally exclusive flavonoids have been 
perceived, in plant sources (Harbone et al., 1975). Flavonoids almost entirely act as 
photoreceptors (Moore, 1989), antifeedants, visual attractors (Hedin and Wangea, 1986), 
antioxidants (Pietta, 2000), bactericides and fungicides (Tomas-Barberan et al., 1988). In 
all vascular plants, water soluble polyphenolic compounds are exist, they are 
biosynthesized from the phenylpropanoid metabolic pathway. As shown in Figure 2.2 
displayed flavonoid fundamentally acquire 15 carbon atoms, through which a linear three 
carbon chain correlates two fused six member rings, a hetrocyclic C ring and an aromatic A 
ring to an aromatic B ring (Patel, 2008). The skeleton of flavonoids delineated as C6-C3-C6. 
 
 
 
                                         
 Figure 2.2: General structure of flavonoid 
 
2.2.2 Main categories and food sources of flavonoids 
Based on chemical structure flavonoids can be classified into six different major 
groups including flavonols, flavones, flavanones, isoflavones, flavanols and anthocyanidins 
(Beecher, 2003). Flavonoids appear consistently in assorted food sources that are exhausted 
frequently in human regime such as vegetables, fruits, beverages and herbs. 
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Table 2.1: Flavonoid classes, chemical characteristics, prominent food and common food 
sources. 
Flavonoid 
classes 
C ring  
unsaturation 
C ring  
functional 
group 
Prominent food 
flavonoids 
Common food 
sources 
Flavonols 2-3 double bond 3-Hydroxy, 
4-Oxy 
Kaempferol 
Quercetin 
Myricetin 
Broccoli, 
Apples, Yellow 
onions, Cherry, 
Tomato 
Flavones 2-3 double bond 4-Oxy Apigenin 
Luteolin 
Green leafy 
spices, Parsley 
Flavanones None 4-Oxy Naringenin 
Hesperetin 
Eriodictyol 
Citrus fruits: 
Orange, Lemon 
Isoflavones 2-3 double bond 4-Oxy Genistein 
Daidzein 
Glycitein 
Legumes, 
Soybeans 
Flavanols 2-3 double bond 3-Hydroxy 
3-O-gallate 
Epicathechin 
Catechin 
Epicathechin-3-
gallate 
Tea, Chocolate, 
Red grapes, 
Cocoa 
Anthocyanidins 1-2, 3-4 double 
bonds 
3-Hydroxy Cyanidin 
Delphinidin 
Berries 
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2.3 Kaempferol 
2.3.1 Introduction 
Kaempferol is a type of flavonoid, a natural flavonol. The melting point of 
kaemferol is 276-278°C with the molecular weight of 286.2 g/mol. It’s a yellow crystalline 
solid which is soluble in hot ethanol and diethyl ether. However, it is hardly soluble in 
water. Winkel-Shirley (2002) considered that kaempferol has a diphenylpropane structure 
(C6-C3-C6) like other flavonoids. Condensation of 4-coumaroyl-CoA (C6-C3) with three 
molecules of malonyl-CoA leads to synthesis of kaempferol.  
 
 
 
 
 
                              Figure 2.3: General structure of kaempferol 
 
2.3.2 Natural sources 
It can be isolated from apples, citrus fruits, onions and leeks, grapes, tea, red beans 
and pinto beans, broccoli, delphinium and other plant sources. 
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2.3.3 Biological activities of kaempferol 
 Cui et al. (2008) reported that high consumption of foods containing kaempferol 
may diminish the risk of developing several types of cancers such as lung, gastric, 
pancreatic and ovarian cancer. Likewise, it has the same effect on cardiovascular diseases. 
They suggested that further studies need to prove protective effect of kaempferol in these 
diseases.  
 
(i) Antioxidant activity 
Several studies have displayed that kaempferol, some glycosides of kaempferol and 
numerous kaempferol containing in plants have antioxidant activity. Rice-Evans (2001) 
mentioned that the important structural features involved in the antioxidant activity of 
kaempferol are the presence of a double bond at C2-C3 in conjugation with an oxo group at 
C4 and the presence of hydroxyl groups at C3. 
In another study Wang et al. (2006) found that kaempferol can be a superoxide 
scavenger, with an IC50 of 0.5 μM. Besides, they mentioned that kaempferol antioxidant 
activity is due to its ability to decrease superoxide levels at low concentrations.  
 
(ii) Anti-inflammatory activity 
Kim et al. (2004) displayed that kaempferol has anti-inflammatory properties like 
other flavonoids. Furthermore, Serhan et al. (2008) reported that chronic inflammation 
occurs, when acute inflammation is not resolved. It has a detrimental effect in numerous 
disease including atherosclerosis, cancer, asthma, and some neurological disorders, such as 
Alzheimer’s disease. 
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Several mechanisms of action play role in the anti-inflammatory activity of 
kaempferol. One of the most important mechanisms is activation of the nuclear factor 
kappa B which is increase the expression of pro-inflammatory cytokines, chemokines and 
enzymes like TNF-α, IL-1, IL-6, IL-8, COX-2 and iNOS (Kim et al., 2010). 
 
(iii) Anticancer activity 
Cemeli et al. (2004) suggested that low concentrations of kaempferol may preserve 
DNA from damage induced by different carcinogens. DNA alteration considered as the 
most accepted view of carcinogenesis that caused cancer.  
Hahn et al. (2002) found that apoptosis resistance, increased angiogenesis, capacity 
of invasion and metastasis leads to formation of a malignant tumor. Additionally, Huang et 
al. (2010) perceived that kaempferol can be inducing apoptosis. The formation of a cancer 
requires that tumor cells develop apoptosis resistance.  
 
(iv) Antimicrobial activity 
Cushnie and Lamb (2005) noted that kaempferol and its glycosides which are 
isolated from plants, used in medicine due to their antimicrobial properties such as 
antibacterial, antiviral, antifungal and antiprotozoal.  
Habbu et al. (2009) perceived that after 7 days oral administration of kaempferol-7-
O-methyl-3-sulphate, the number of survived mice which were infected with the bacteria 
Klebsiella pneumonia significantly increased. Some investigations displayed that 
kaempferol has anti-viral activity against numerous viruses, including herpes simplex virus 
(Lyu et al., 2005), cytomegalovirus (Mitrocotsa et al., 2000), influenza virus (Jeong et al., 
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2009) and human immunodeficiency virus (HIV) (Min et al., 2001). Barbosa et al. (2007) 
described that kaempferol has antiprotozoal activity. Furthermore, Marin et al. (2009) 
showed that this activity is against Leismania spp, Entamoeba histolytica and Giardia 
lamblia.  
 
(v) Other biological activates 
 Consumption of kaempferol containing foods is associated with a decreasing in 
mortality from coronary heart disease. It can be reduce risk of coronary heart disease cause 
to death, incidence of myocardial infarction and incidence of cerebrovascular disease (Lin 
et al., 2007; Marniemi et al ., 2005). Other studies by Belguith-Hadriche et al. (2010) 
suggested that kaempferol and some of its glycosides may decline triglycerides levels, 
cholesterol levels and body weight. Ghaffari and Mojab (2007) broadcasted that kaempferol 
glycosides and numerous kaempferol containing in plants have antidiabetic activity, it can 
be inhibit diabetic complications.  
 
2.4 AChE inhibitory activity and other accessible health advantages of flavonoids 
One of the various group of phytonutrients that have been extensively studied for 
human health are flavonoids, due to their instrumental medicinal properties, such as 
antioxidant (Pietta, 2000), anti-inflammatory (Jung and park, 2007)  and AChE inhibitory 
activity (Tim Cushnie and Andrew, 2005).  
During a study Jung and park (2007) reported that flavonoids from Agrimonia 
pilosa ledeb possess significant AChE inhibitory activity.  Exclusively, AChE inhibitory 
activity of quercetin was twice as dehydroevodiamine. Further research by Khan et al. 
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(2009) proved that flavonoid derivatives, quercetin and macluraxanthone have AChE 
inhibitory activity with different deals of characteristics.  
Flavonoids due to their estrogenic activities have been considered as successors for 
estrogen (Miksicek, 1993), beside that some flavonoids such as apigenin and kaempferol 
illustrated strong neuroprotective effects in the brain versus Aβ association and Aβ impel 
cell death (Zhu et al., 2007). Thus, one of the most beneficial natural compounds could act 
important role against Alzheimer’s disease are flavonoids (Ji and Zhang, 2006).   
Besides the biological actions noted above, flavonoids have been prevalent to 
exploit many other effects including antitumor, anticancer, anticarcinogenic, 
antihepatotoxic, antiallergic, antiatherosclerotic, antithrombotic, antihypertensive and 
antiarrhythmic activity (Formica and Regelson, 1995). Flavonoids have the quiescent to be 
an admirable candidate in pharmaceutical drug augmentation against AD due to their 
discrete explorations on the biochemical and pharmacological properties.  
 
2.5 Alzheimer’s disease (AD) 
2.5.1 Introduction 
Alzheimer’s disease is a chronic neurodegenerative disorder.  Many investigations 
demonstrated that it causes degradation in cognitive functions for instance in concentration, 
language skills, learning, reading and writing. This is associated with the deterioration in 
non-cognitive competence which induces personal changes, behavioral abnormalities, 
biological disability, neurological disturbances and ultimately death (Tariot, 1994; 
McGleenon et al., 1999; Jung and park, 2007). AD is one of the major causes of death, 
especially for the people over 65 years old in the world (Launer et al, 1999). It is a 
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neurodegenerative brain disease that insidiously robs patients of their cognition, function, 
independence identity and results in morbidity and eventual mortality (Henley et al., 2012). 
In 2007 Brookmeyer and colleagues broadcasted that AD is the most dominant 
cause of dementia and reports for roughly 60 to 80 % of cases in our aging population. 
They assessment by linear extrapolation there is 33.9 million AD patient worldwide in 
2011. Barnes and Yaffe (2011) predicted that AD would be increase exceedingly in the 
next future. At the age of 60 AD pervasiveness is around 1% and its contingency doubles 
every 5 years after age 65. 
Extensively AD is classified into several clinical forms such as sporadic AD 
includes 85 to 90 % of cases with late onset, AD affiliated with Down’s syndrome and 
familial AD indicates approximately 5% of AD patients with early and late onset 
(Khachaturian, 1985). 
 
2.5.2 The physiopathology and neuropathology of AD 
The pathogenesis of AD has not been absolutely ascertained due to its complexity. 
Benzi and Moretti (1998) demonstrated that AD was evidently delineated pathologically by 
the severe loss of neuronal and synaptic cells, the presence of neurofibrillary tangles and 
cerebral Aβ. 
(i) Synaptic and neuronal cell death 
The cholinergic hypothesis of Alzheimer’s disease was endowed hence early 
1970’s. Silvestrelli and colleagues (2006) mentioned that the features, cognitive 
dysfunction, behavioral and functional annoyances in AD patient may due to discerning 
impairment on cholinergic neurotransmitter systems. The depletion of acetylcholine mainly 
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caused cholinergic inadequacy, which could be overflow AChE activity and resulted cell 
death in cholinergic basal forebrain system.  
In other researches indicated by Beeri et al. (1995) exuberance of AChE were 
adapted the structural features of neuromuscular junctions in transgenic Xinopus tadpoles. 
Additionally they displayed memory and learning impairment in transgenic mice. 
Otherwise, Hohmann and colleagues (1988) discovered that high affinity choline uptake in 
cortical areas and significant deficiency in AChE activity was persistent with the extensive 
neuronal loss especially in nucleus basalis of AD patient. Whitehouse et al. (1986) 
recognized that progressive memory and cognitive deterioration in AD were due to severe 
and consistent loss of nicotinic receptors.  
 
(ii) Neurofibrillary tangles (NFT) 
Abnormal microtubule associated tau protein made by neurofibrillary tangles which 
are double helical filaments. Hernandez and Avila (2007) reported that phosphorylated tau 
proteins by stabilizing microtubules help to growth and development of axon in normal 
cells. Nonetheless, inside the soma of neurons hyperphosphorylated tau proteins begin to 
pair and link with other tau protein threads to assemble neurofibrillary tangles. They 
consistently placed in the parietotemporal region, hippocampus, the frontal affiliation 
cortices and medial temporal lobe. Some studies illustrated that by collapsing the neuronal 
transport system, the microtubules become degenerate and ultimately leads to neuronal cell 
annihilation (Iqbal et al ., 2005; Cummings, 2004).  
Silvestrlli et al. (2006) displayed that the density of NFT within neurons in brain 
precisely related with the dangerousness of dementia. Furthermore, Hardy and Selkoe 
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(2002) during a study hypnotized that different alleles of a gene may generate forms of tau 
protein that prone to become tangles, although the role of tau protein and NFT formation in 
the access and progression of AD are still ambiguous. 
 
(iii) Neuritic plaques (Amyloid plaques) 
Benzi and Mretti (1998) declared that dense and insoluble amyloid beta peptide 
protein (Aβ), glial elements and dystrophic neuritis are neuritic plaques. Furthermore, 
Silvestrelli et al. (2006) considered that Aβ is a peptide fragment borrowed from sequential 
proteolysis of the larger Aβ precursor protein (APP) by β-secretase and γ-secretase. Selkoe 
and Schenk (2003) discussed that APP is encoded by a gene located on chromosome 21, 
it’s a transmembrane glycoprotein that concentrates in neuronal synapses. Some 
investigations suggested that Aβ fibers which produce  Aβ fragments,  formerly combined 
and figure Aβ plaques and drop between nerve cells within extracellular spaces (Ohnishi 
and Takano, 2004: Tiraboschi et al., 2004). 
In keeping with Hensley et al. (1994), in vitro studies notify that Aβ leading to the 
excessive membrane lipid peroxidation and oxidative damage to the brain cells by 
stimulating the generation of free radicals. The experiments exhibiting Aβ deposition, 
cholinergic disorder, memory impairment, neurotoxicity and formation of fibrillary tangles, 
have been supported by the idea of Aβ is one of the culprits leading AD (Giovannelli et al., 
1995; Frautschy et al., 1996). Recent researches by Alzheimer’s Association in 2011 
including that Aβ plaques and tangles may form in old generations, however, incline to 
develop far more in AD patient.  
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Farlow (1998) broadcasted that numerous other prominent factors contribute to 
pathogenic process of AD, including mild cognitive impairment, inflammation, oxidative 
stress, cardiovascular disease risk factors, traumatic brain injury and estrogen hormone 
deficiency. 
 
2.5.3 Warning signs of AD 
In 2009 a list of ten warning signs of Alzheimer’s disease that can serve as a 
guideline to help distinguish AD sufferers created by the Alzheimer’s Association of 
United States and Alzheimer’s disease Foundation of Malaysia.  
I. Changes in characteristic and attitude. 
AD sufferers can become calmly suspicious, confused, nervous or depressed 
with people and their surrounding environment. 
II. Short term memory impairment. 
AD patients regularly lose track of dates, events and information that they 
learned recently.  Frequently, they may ask for the same counsel and wait for 
memory assistants or their relatives to handle the things they used.  
 
 
 
III. Poor judgments and decision making. 
People with AD may incompetent to manage their current budget, for instance 
they pay wrong amounts of money. They may have less responsibility about 
grooming and self-cleanliness. 
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IV. Problem in recognizing visual image and spatial relationships. 
Vision problems, feeing hard in judging distance, reading and identifying colors 
noticed in AD patients.  
V. Misplacing things and being unable to reiterate steps. 
A person with AD not be able to fetch the things again, they may put things in 
improper places or lose things. 
 
VI. Problems in vocabulary and language in writing or speaking. 
Forgetting simple words or use wrong words, making incomprehensible 
sentence and unable to continue or follow a conversation properly are signs of 
AD. 
VII. Complexity in solving problems or planning. 
Some AD patient cannot contemplate and take longer time to do things than 
they did before. They may have problems to deal with numbers, develop or 
follow a plan. 
VIII.  Dilemma in achieving familiar tasks. 
It’s difficult for AD sufferers to fulfill daily tasks for instance walking to a 
familiar place, turning on the television or remembering a favorite game’s rules. 
 
 
IX. Bewilderment with place or time. 
People with AD perplexed with date and time. They may become lost readily by 
forgetting where they are, how they got here and how to get home. 
X. Departure from social activities or work. 
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AD patient may begin to avert social activities, hobbies or sports due to the 
changes they have expert. 
 
2.5.4 Treatments for AD 
Alzheimer’s Association of United States in 2007 demonstrated that AD cannot be 
cured by any definitive drug treatments. Nonetheless, United States Food and Drug 
Administration (FDA) have been approved two main types of medication to ameliorate 
symptoms of AD, AChE inhibitors and N-methyl-D-aspartate (NMDA) receptor 
antagonists. 
Memantine (Namenda) was the first drug of the NMDA receptor antagonist type 
certified by FDA for treatment of moderate to severe AD. Alzheimer’s Association of 
United States in 2007 broadcasted that Memantine protect brain’s nerve cells against excess 
glutamate, it acts by adjusting the activity of glutamate. This is because excess glutamate 
can arouse NMDA receptor and leads to the excess entry of calcium into nerve cells. This 
can causes degeneration of nerve cells. Memantine could prevent such destructive sequence 
by locking NMDA receptor. Generally, Memantine is well tolerated however, some 
common side effects such as headache, confusion, dizziness and constipation repots by 
Alzheimer’s Association of United States.  
Recently, many studies released that could act as potential future treatments of AD. 
For instance, Craft et al. (2011) declared that Aβ could be reducing by administrating of 
intranasal insulin which helps to improve brain glucose metabolism. Moreover, Krohn et al. 
(2011) asserted that Aβ formation can reduce by activating of membrane transport protein 
ABCC1. This leads to blocking neurodegeneration that causes dementia in AD patient.  
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2.6 Acetylcholine (ACh) 
Ekman (2001) considered that an important neurotransmitter that serves both 
peripheral nervous system (PNS) and central nervous system (CNS) of most organisms is 
ACh. Regularly, ACh involves in memory, learning and mood, in CNS (Silvestrelli et al., 
2006). In PNS, ACh function is division of somatic nervous system and it’s a major 
neurotransmitter in autonomic nervous system. Therefore, smooth muscle, cardiac muscle 
and skeletal muscle movement regulates by ACh (Ekman, 2001). Despite of that, it has 
inhibitory effect in heart however, with excitative effect at neuromuscular junction. 
In presynaptic cholinergic nervous ACh is synthesized from acetyl coenzyme A and 
choline via the reaction of choline acetyltransferase. Rosenfeld and Loose (2007) suggested 
that ACh packaged into synaptic vesicles and discharged into synaptic cleft through 
calcium dependent exocytosis upon the arrival of nerve impulse at presynaptic axon 
terminal. Consequently, ACh diffuses across synaptic cleft to bind, activate or inhibit 
acetylcholine receptors found on another adjacent muscle cell or neuron. 
Muscarinic and nicotinic receptors are the two main families of cholinergic 
receptors. As noted by Golan (2008) muscarinic receptors are G-protein coupled receptors 
and mainly located in the CNS, autonomic ganglia, terminal synapses of all 
parasympathetic postganglionic fibers and a few sympathetic postganglionic fibers. Effect 
on cardiac muscles, smooth muscle and secretory exocrine glands due to the binding of 
ACh on tissue muscarinic receptor excites the parasympathetic or cholinergic. During a 
study Okpako (1991) discussed that parasympathetic effects include lower heart rate, 
bronchi contraction, lower blood pressure, stimulation of gastrointestinal motility and 
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secretion. In another research Purves et al. (2012) reported that nicotinic receptors are 
ligand gated ionotropic receptors that are largely concentrated at CNS, autonomic ganglia, 
adrenal medulla and neuromuscular junctions. Ekman (2001) observed that the voluntary 
skeletal muscle concentration was due to binding of ACh to nicotinic receptor at 
neuromuscular junctions and autonomic ganglia. 
Cholinesterase like AChE and butyrylcholinesterase can be hastily degrading ACh. 
Hydrolysis of ACh leads to nerve impulse signaling at postsynaptic cells manifests in 
convenient timing and prevent excessive stimulation adjacent to the muscle cell or neuron.  
 
2.7 Acetylcholinesterase (AChE) 
(i) Introduction 
ACh promptly break down into choline and acetic acid by AChE. Foye et al. (2007) 
reported that the resulting choline is recycled through reuptake back into presynaptic nerve 
terminal for use in producing new ACh, since acetic acid hastily diffuses into the 
surrounding medium. AChE could hydrolyze the neurotransmitter acetylcholine due to its 
protease activity. AChE has high catalytic activity it could hydrolyzed 4×105 molecules of 
acetylcholine in one minute (Golan et al., 2011). 
Conforming to Zimmerberg (1998) variety chemical structure of AChE leads to 
exists in hydrophilic and hydrophobic types. The hydrophilic species of AChE that 
frequently works within the cell break down the excess intracellular ACh. Quick 
inactivation of ACh at synaptic cleft or neuromuscular junction accomplished with the 
hydrophobic species of AChE is concentrated within post synaptic membrane adjacent to 
post synaptic receptor. Otherwise, Soreq and Seidman (2001) broadcasted that 
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administration of AChE in red blood cells leads to releasing the ACh and cholinoceptive 
neurons in brain. 
Appleyard (1992) mentioned that AChE is an important key in cholinergic 
transmission, additionally, he proved that it has multifarious other ‘non-classical’ activities. 
Besides that Soreq and Seidman (2001) suggested AChE role includes in neuritogenesis, 
thrombopoiesis and promotion of amyloid fiber assembly. In another study Att-ur Rahman 
(2001) declared that AChE has capability in degrading ACh, accordingly, it is often 
regarded as an attractive target for the discovery of mechanism based inhibitors and rational 
drug design for the treatment of diseases that involve impaired of ACh mediated 
neurotransmission, such as AD and dementia. 
 
(ii) AChE activity 
AChE activity was used to examine by several methods. One of them is Michel’s 
method which needs sensitive pH meter and large samples (Michel, 1949). Another one is 
Ellmam’s method the most simplest and popular technique was developed by George 
Ellman in 1961. This is the method needs micro size samples and well functioned 
laboratory spectrophotometer (Ellman et al., 1961) or ELISA. 
In Ellmam’s method, the solution prepared by adding test sample, AChE, 5,5’-
dithiobis-2-nitrobenzoic acid (DTNB) and acetylthiocholine iodide (ATCHi). The, AChE 
breaks down ATCHi into thiocholine and acetic acid, primarily. Then, yellow colored 
compound known as 5-thio-2-nitrobenzoate (TNB) produce due to reacting thiocholine 
with DTNB which the maximum absorbance is at 412nm (Yang et al., 2011). 
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Acetylthocholine + H2O                                              Acetic acid + Thiocholine 
Thiocholine + DTNB                                                     5-thio-2-nitrobenzoate (yellow color)                                                                                
                                                                               + 2-5 mercapto thiocholine-nitrobenzoate  
               
(iii) AChE inhibitors 
Carbamates, tertiary amino compounds and organophosphates are three major 
categories of AChE inhibitors. Based on their mechanism of inhibition actions and 
chemical structures AChE inhibitors divided to 3 categories (Benzi and Moretti, 1998). 
Metcalf (1971) reported that carbamats are pseudo irreversible inhibitors which form a 
carbamoylated enzyme inhibitor complex with serine residue of AChE, hence inhibiting 
AChE activity such as eptastigmine. Benzi and Moretti (1998) declared that tertiary amino 
compounds are reversible inhibitors ether non-competitive or mixed type that can cause 
allosteric inhibition of AChE such as donepezil and tacrine, respectively. Fukuto (1990) 
mentioned that irreversible inhibitors that can form a stable phosphorylated enzyme 
inhibitor compound are organophosphates such as malathion. This group has serine residue 
of AChE via covalent bonds, it prohibit hydrolyze of ACh by AChE. 
Yang and colleagues (2011) has reported that an alkaloid skimmianine from 
Zanthoxylum nitidum roots has strong AChE inhibitory activity. They indicated that anti 
acetylcholinestrase activity of skimmianine may be effective in the treatment of Alzheimer 
disease. Kim and colleagues (2002) reported that methanol extract from the roots of 
Angelica dahurica has significant AChE inhibitory activity. 
Another study carried out by Kim and colleagues (2004) showed that alkaloid of  
corynoxidine, protopine, palmatine, and berberine which have been isolated from aerial 
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parts of Corydalis speciosa have possessed AChE inhibitory activity. Similarly, Lee and 
colleagues (2004) have found that taraxerol and scopoletin from methanol extract of 
Vaccinium oldhami have AChE inhibitory activity. 
Liu and colleagues (2011) investigated on extract of Styrax agrestis fruits showed 
that 3 new egonoltype benzofurans: egonol-9(Z), 12(Z) linoleate, 7-demethoxyegonol-
9(Z),12(Z) linoleate , and 7-demethoxyegonol oleate exhibited significant AChE inhibitory 
activity. Pereira and colleagues (2010) have determined the water extract of alkaloids from 
leaves of Catharanthus roseus strongly inhibited AchE. They have also reported that the 
roots extract of C. roseus may constitute a promising source of compounds with 
pharmaceutical interest. 
In another study by Wang and colleagues (2007) have found that strong anti-AChE 
activity compound (hydroquinone) in dried rhizome chloroform extract of Rhodiola rosea. 
A similar strong AChE inhibiters reported by Mukherjee and colleagues (2007) known as 
huperzine-A, galantamine, a-viniferin and ursolic acid was obtained from Huperzia serrata, 
Galanthus nivalis and Narcissus sp, Caragana chamlague and Origanum majorana, 
respectively. 
The amount of ACh which is available to deliver nerve messages in axonal transport 
is reduced by the destruction of brain cells that produce and use ACh in AD. Stahl (2000) 
suggested that AChE inhibitors are extensively employed to avoid AChE from hydrolyzing 
the released ACh, thereby the ACh level available at cholinergic synapse and 
neuromuscular junction enhance and it leads to increasing cholinergic transmission.  
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(iv) AChE inhibitors for the treatment of AD  
Wang and colleagues (2009) has also investigated on huperzine-A, an alkaloid 
isolated from the Chinese herb Huperzia serrate. It has high AChE inhibitory activity, with 
300–500 µg per day of huperzine A could be effective in treatment of AD. Luttmann et al 
(2002) reported that in cholinergic nervous system, neuromuscular junction and AChE by 
swift hydrolysis of neurotransmitter acetylcholine in the synaptic cleft is due to termination 
of nerve impulse transmission. 
One of the strategies could reverse memory impairment of AD patients is treatment 
with AChE inhibitors (Kasa et al., 2000). The bioassay results broadcasted by Hong and 
colleagues (2010) showed that novel compounds of phenyl N-methylcarbamate have high 
AChE inhibitory activity at the concentration of 100 mg/L. Bruhlmann and colleagues 
(2001) have tested monoamine oxidase (MAO) as AChE inhibitors and they found that 
these compounds might decrease Aβ deposition causes to treatment of AD.  Finkel (2004) 
mentioned acetylcholine dysfunction is one of the consequences of AD and it makes AChE 
inhibitors effective for AD treatment. García-Ayllón and colleagues (2011) have reported 
that AChE is due to decreasing in acetylcholine has important role in AD treatment. 
Silvestrelli et al. (2006) broadcasted that the cholinergic hypothesis of AD has act as 
a powerful encouragement to pharmacotherapeutic strategies of AD, which focus on 
improving the cholinergic inadequacy and potentiating residual activity in affected neuronal 
circuits by reforming cholinergic transmission. 
For amplifying cholinergic activity in brain by maintain ACh level, AChE inhibitors 
has been widely pursued as the most powerful approach. Loizzo et al. (2008) discussed that 
in AD patients, AChE inhibitors could minimize the formation of neurotoxic fibrils and 
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clumping of Aβ, hence AChE inhibitors might be useful in treatment cognitive symptoms 
of AD (Kalauni et al., 2002; Atta-ur-Rahman et al., 2004).  
FDA certified three types of AChE inhibitors for treatment of AD, including 
Donepezil (Aricept), accepted in 1996, Rivastigmine (Exelon), accepted in 2000 and 
Galantamine (Reminyl), accepted in 2001. The first AChE inhibitor approved was Tacrine 
(Cognex) in 1993 however, due to its unfavorable side effects, like liver damage it 
occasionally prescribed nowadays (Alzheimer’s Association of United States, 2007). 
On the other hand benefits of AChE inhibitors were mentioned by publications of 
Alzheimer’s Association of United States (2007). For instance, block the activity of another 
enzyme participating in degradation of ACh, by rivastigmine, galantamine capable of 
promoting ACh release and thereby support the response of certain message receiving 
nerve cells to ACh. However, in plentiful clinical trials AChE inhibitors have been studied 
on AD patients and results displayed that taking these drugs as medications achieved feeble 
improvement in thinking and memory. AChE inhibitors may postpone the progression of 
AD approximately six months to a year.  
Sung et al, (2002) considered that due to short half- lives or unfavorable side effects 
of AChE inhibitors they have small degree of benefits and limited clinical uses, either. 
According to Alzheimer’s Association of United States (2007) AChE inhibitors unable to 
terminate the underlying damage of nerve cells and reverse AD. Therefore, their capability 
in improving AD is reducing brain cell destruction progresses.   
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2.8 Animal study 
(i) Introduction 
Using animal (ICR mice) might be beneficial to improve AChE inhibitors in 
treatment of AD. Dong and colleagues (2005) investigated two AChE inhibitors 
physostigmine and donepezil on memory related behaviors of mice. They suggested that 
AChE inhibitors could improve memory deficits in mice. In another study by Ikarashi and 
colleagues (2004) have examined mice memory disturbance by measuring AChE 
concentrations in their brains. They founded that memory impairment in cholinergic system 
of the mice is due to Aβ accumulation when AChE increased. Figueiró and colleagues 
(2010) have extracted AChE inhibitors from Ptychopetalum olacoides and orally gave these 
compounds to the mice. They improved meaningful AChE inhibitor activity of these 
extracts for treating neurodegenerative conditions which is useful for AD treatment. 
 
(ii) Radial arm maize (RAM) 
Olton and Samuelson (1976) constructed the radial arm maze to assess memory and 
spatial learning in mice. The archetype apparatus has eight equal arms, and all of them 
branching from a petite round central platform. There is a food section at the end of each 
arm, which is not noticeable from the basic platform.  Furthermore, they illustrated that 
mice have peachy memories for visited and unvisited arms; on average the mice had 88% 
correct entries, in their first 8 decision they had approximately 7 new entries.     
Levin (1988) suggested that radial arm maze is a practicable memory testing for 
displaying the effect of drugs. In another study Foti et al, (2011) considered that the radial 
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arm maze can be analyzed via movement most aspects of the spatial function, as the 
analytical memory and the appropriate working memory. 
 
Figure 2.4: The mice in the radial arm maze 
 
 
 
 
 
 
               Figure 2.5: Radial arm maze         
 
 
 
Arm of the maze 
Pellet 
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Objectives of the study 
1. To determine AChE inhibitor activity in Aquilaria subintegra for treatment of 
Alzheimer’s disease (AD).  
2. To isolate and characterize the chemical compounds present in Aquilaria subintegra that 
inhibits AChE. 
3. To observe the effect of AChE inhibitors in mice. 
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CHAPTER 3 METHODOLOGY 
 
3.1 Plant materials  
The leaves and stem of Aquilaria subintegra were collected from RAL plantations 
farm in, Kuala Kangsar, Perak, Malaysia. The authentic of the plant sample was verified by 
plant taxonomist Professor Dr. Ong Hean Chooi from the Institute of Biological Science, 
Faculty of Science, University of Malaya.  
 
3.2 Chemicals 
Acetylcholinesterase (EC3.1.1.7, Sigma product no C2888), acetylthiocholine 
iodide (ATCI), 5,5’-dithiobis [2-nitrobenzoic acid] (DTNB), and Berberine were purchased 
from Sigma (St. Louis, MO, USA). Standard kaempferol purchased from Calibiochem 
(Japan). TLC Silica gel 60 F254 (Merck KGaA, Germany).  
 
3.3 Extraction and isolation of chemical compounds 
The leaves, stem and fruit of Aquilaria subintegra were powdered and extracted 
with chloroform, methanol and distilled water. 1 L of chloroform, methanol and water was 
used to extracted leaves and stem powder, for 2 hours in water bath at 40°C. Then each 
sample extract was filtered and the filtrate was concentrated to 10 ml using rotary 
evaporator with medium speed at 40°C. Then 1 ml of each sample was evaporated to 
dryness for crude extract preparation.  
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3.4 Detection of the chemical compounds 
(i) Visible light 
The separated bands occurred on TLC plates were determined under visible light. 
Then Retention Factor (Rf) value of each band calculated by using the formula:  
Rf = Distance traveled by the substance (cm) / Distance traveled by the solvent (cm) 
(ii) UV Light 
For detecting ultraviolet active absorbing spots TLC plates were perceived under 
ultraviolet (UV) light.  
(iii) Chemical reagents 
 
a) Folin-Phenol 
50 ml of Folin-Ciocalteu mixed with 50 ml of distilled water for preparing Folin-
Phenol.   It used to detect phenols on TLC plates after spraying with the manifestation of 
blue bands. 
b) Vanilin-H2SO4 
For preparing Vanilin-H2SO4 mixture of 1g of Vanilin and 1.5 ml of H2SO4 added 
to 100 ml of ethanol. Then the mixture has smoothly shaken to dissolve all to become a 
solution. After spraying Vanilin-H2SO4 on TLC plates they need to be heated on a hot plate 
at 100°C for 5 minutes. The exhibition of blue or purple bands announced the presence of 
terpenoids. 
c) Dragendroff’s 
5 ml of solution A and 5 ml of solution B with 20g of acetic acid and 70 ml of 
distilled water were mixed for preparing Dragendroff’s. Solution A was prepared by 
dissolving 1.6g of Bismuth Nitrate into 100 ml solution of water acetic acid. Solution B 
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was made by dissolving 40g of Potassium Iodide into 100 ml of distilled water. 
Dragendroff’s used to detect alkaloids on TLC plates after spraying with presence of 
orange bands. 
 
3.5 Determination of bioactive compound by TLC and LCMS/MS 
TLC plates with height and wide of 20 cm were used. The crude extract was spotted 
as a thin line on the sample line by using a tapered capillary. Then the TLC plate was 
transferred to well covered tank with using chloroform and 10% methanol in chloroform as 
a solvent respectively. When the sample was raised up the plate, the separated bands 
appeared on each plate were identified under visible light and UV light. Then Rf value of 
each band was calculated. Finally reagents of Dragendroff’s, Vanillin-H2SO4 and Folin-
Phenol used to detect alkaloids, terpenoids and phenols respectively. LCMS/MS (Perkin 
Elmer Flexar FX-15 ultra-high performance liquid chromatography (USA) with AB Sciex 
3200Qtrap tandem mass spectrometry (Singapore) used to detect the chemicals presence in 
the leaves and stem of chloroform crude extract with concentration of 5mg/ml. Column: 
Phenomenex Aqua C18 – 50mm x 2.0mm x 5uM; Buffer: A: Water with 0.1% formic acid 
and 5mM ammonium formate, Buffer B: Acetonitrile with 0.1% formic acid and 5mM 
ammonium formate. Gradient run program: 10% A to 90% B from 0.01min to 8.0min, hold 
for 2 min and back to 10% B in 0.1min and re-equilibrated for 5min. The sample extracts 
were diluted two times with appropriate solvents, and filtered with 0.2uM nylon filter prior 
to analyses. MS/MS method: Negative ESI, with -4500kV, temperature at 500°C, purified 
nitrogen gas as nebulization and collision gas 99.9995% purity, fragmentation energy: 
Collision energy spread -35eV +/- 15eV. The data analysis was performed using AB Sciex 
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Analyst 1.5 software with internally built MS/MS library search and further interpretation 
and processing via ACD/Labs MS fragmenter software.  
 
3.6 Determination of total phenols and total flavonoids contents 
(i) Total phenols contents 
The total of the phenolic content was measured according to the method as 
described by Thind et al. (2011). Briefly, 500µl of each crude extract (5mg/ml) was mixed 
with 5 ml Folin ciocalteu (1:10, V/V diluted with distilled water) and 4 ml of 1M sodium 
carbonate. The mixture was incubated in water bath at 45°C for 15 min, and then its 
absorbance was determined at 765 nm by using spectrophotometer. The standard 
calibration curve was prepared by using 0, 50, 100, 150, 200, 250 and 500 mg/L solution of 
gallic acid in methanol: water (50:50, V/V). The experiments were done in triplicate. 
 
(ii) Total flavonoids contents 
The total of the flavonoids content was measured according to the method as 
described by Zhang et al. (2009). Briefly, 500µl of each crude extract (5mg/ml) was added 
to 0.3ml of 5% sodium nitrate. The mixture was incubated at room temperature for 5 min. 
Then, 0.3 ml of 10% aluminum chloride was mixed into the solution before incubated again 
at room temperature for 6 min. Subsequently, the mixture was added with 2 ml of 1 M 
sodium hydroxide and 10 ml distilled water. Absorbance was read at 510 nm using 
spectrophotometer. The standard calibration curve was performed by using 0, 200, 400, 
600, 800, 1000 and 2000 mg/L quercetin solution in methanol. The experiments were done 
in triplicate. 
34 
 
3.7 Toxicity assay 
3.7.1 Brine shrimp lethality assay (BSLA) 
The toxicity test of crude extract was carried out using brine shrimp lethality assay 
(BSLA). The artificial sea water was prepared by dissolving 38 g sea salt in 1 L of distilled 
water. After filtering it, the brine shrimps (Artemia salina) eggs were added and keep in 
dark environment. They were allowed to hatch by incubation at room temperature for 48 h. 
three concentrations of each crude extract (1000µg/ml, 100µg/ml, 10µg/ml) were 
transferred to each vial of microplate with 5 ml of sea water and 10 brine shrimps in each 
vial. The control was also conducted simultaneously and prepared by replacing the crude 
extract with sea water (Atta-ur Rahman et al., 2001). After 24 h the number of surviving 
shrimps was counted and data were analysed using probit analysis program to determine 
the median lethal concentration (LC50). The experiments were done in triplicate.  
 
3.7.2 Toxicity test on mice 
(i) Mean body weight  
Mice were randomly divided into 8 groups. Each group had 3 male and female 
mice. Group 1: control; Group 2, 3 and 4 leaves and stem crud extracts were given by oral 
gavage at doses of 0.1ml/g body weight, 0.5 ml/g body weight and 1 ml/g body weight 
respectively, for a period of at least 28 days (Kushwaha  et al.,  2010). The mean body 
weight of each group was measured each day during the study. The mean body weight of 
mice was analyzed by ANOVA, p values of <0.05 were used to indicate a significant group 
differences.  
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(ii) In-life observations 
Once in a day from cage-side mortality and general condition included: mice 
appearance, activity, behavior, respiration, skin, fur, eyes, nose, oral activity, abdomen and 
external genitalia were perceived for any sign of toxicity. During the study, once in a week 
mice were removed from their cages   for observation of mortality and general condition 
following the method as described by DeMerlis et al. (2005). 
 
3.8 AChE inhibitory activity assay 
Ellman’s method as described by Yang et al. (2011) was used for AChE inhibitory 
activity of the crude extract and isolated compound of kaempferol 3,4,7-trimethyl ether 
from stem chloroform extract. Concisely, 140 µl of 0.1 M sodium phosphate buffer, with 
pH 8 and 20µl of 1 mg/ml sample solution mixed with enzyme (AChE). The Amount of 
AChE used was 15 µl with activity of 0.25 U/ml. They were pre incubated at 4°C for 20 
min. The reaction was started by adding 10 µl of 0.01 M DTNB and 10 µl of 0.075 M of 
ATCI. Then the extract was incubated at room temperature for 20 min. After that the 
absorbance at 405 was measured with ELISA. The percentage of inhibitory activity was 
calculated by using formula: 
% of AChE inhibitor = Ac – At / Ac × 100   
Berberine was used as positive control. The experiments were done in triplicate.  
3.9 Animal study 
The male and female adult (2 months old, 35–45 g) ICR mice were obtained from 
the Animal House, University of Malaya. The mice were sustained under controlled 
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environmental conditions with a temperature of 22±1 °C, 12-h light/dark cycle and food 
and water accessible ad libitum. During the 3 months study, the mice were divided to 12 
groups. Each group had 3 male and female. Group 1: control; Group 2: stem extract; Group 
3: leaves extract; Group 4: leaves plus stem extract; Group 5: kaempferol and Group 6: 
berberine. Each extract and standard was given by oral gavage to the mice group 
respectively. Valium was used to impair the memory of the mice. All drugs were given at 
doses of 0.1 ml/g body weight. The animal test was conducted in an eight-arm radial maze 
apparatus with eight arms a radial maze (Figure 2.4). The central hub is consisted of a white 
polypropylene octagonal base (28.6 cm in diameter, 11.4 cm sides). The arms radiated from 
the center hub, with equal spacing between each arm. Each arm was 76.2 cm long and 8.9 
cm wide with clear polycarbonate walls (17.5 cm high). Each baited arm had only one 
pellet.  The working memory was assessed by measuring the number of repeat entries to 
arms of the maze already visited (NRE). For instance if NRE is 5 it means that the mouse 
eats all 8 pellet with 5 times comes back to the arms of the maze which is the pellet was 
eaten before (5 errors). The number of entries until the first error occurs (NEF) is 
commonly used as an additional measure of performance in radial arm maze. For instance 
if NEF is 6 it means that the mouse eats 6 pellet without any repeated entries to the arms of 
the maze that the pellet was eaten before. However, the mouse eats the 7
th
 pellet after some 
repeated entries to empty arms.  Each group was first given valium. After 30 min it was 
placed in the radial arm maze. Then after 1 hour the mice was given the test sample and 
was placed again on radial arm maze. Each mouse was kept in radial arm maze for 10 min. 
The results of the memory testing data were analyzed with ANOVA, p values of <0.05 
were used to indicate a significant group difference in all analyses. 
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CHAPTER 4 RESULTS 
 
4.1 TLC and LCMS/MS 
The thin layer chromatography (TLC) of chloroform and methanol extract of leaves 
and stems showed the presence of phenols, flavonoids and alkaloids compounds (Tables 
4.1; 4.2; 4.3; 4.4; 4.5; 4.6; 4.7; 4.8; 4.9; 4.10; 4.11; 4.12; 4.12; 4.13; 4.14; 4.15; 4.16; 4.17; 
4.18). The analysis of the chloroform leaves extract with LCMS/MS showed that it contain 
Delphinidin-3-glucoside (Figure 4.2), 2(3,4-Dihydroxyphenyl)-7-hydroxy-5-benzene 
propanoic acid (Figure 4.3) and benzenepropanoic acid conjugate (Figure 4.4). Whereas, 5-
Hydroxy-7,4-dimethoxyflavone (Figure 4.6), kaempferol 3,4,7-trimethyl ether (Figure 4.7) 
and 5.7-Dihydroxyl-4’-dimethoxyflavone (Figure 4.8) was presence in the stem chloroform 
extract. 
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Table 4.1: Thin layer chromatography of methanol extract from Aquilaria subintegra fruit in methanol solvent 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
A1 0.58 Yellow(+) Purple(+) 
- - - 
- 
A2 0.65 - 
Yellow(+) - - - 
- 
A3 0.74 - 
Yellow(+) - - - 
- 
A4 0.79 Yellow(+) 
Purple(+) - - - 
- 
A5 0.88 Yellow(+) 
Purple(+) - 
Purple(++) 
- 
Terpenoid 
A6 0.97 Yellow(+) 
Yellow(+) - 
- 
- 
- 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.2: Thin layer chromatography of methanol extract from Aquilaria subintegra fruit in chloroform solvent 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 
 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin- 
Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B1 0.61 - Yellow(+)* 
- 
Blue(+) 
- 
Terpenoid 
B2 0.68 
- 
Purple(++) 
- 
Blue(+) 
- 
Terpenoid 
B3 0.82 
- Yellow(+) - 
Purple(+) 
- 
Terpenoid 
B4 0.85 
- Yellow(+) - 
- 
- 
- 
B5 0.89 
- Yellow(+) - 
- 
- 
- 
B6 0.95 
- Yellow(+) - 
Blue(+) 
- 
Terpenoid 
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Table 4.3: Thin layer chromatography of methanol extract from Aquilaria subintegra fruit in 10% methanol in chloroform solvent 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-
Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C1 0.046 Yellow(++) - Blue(+) Blue(++) - Phenolic/terpenoid 
C2 0.153 Yellow(+) Purple(+) - - Orange(+) alkaloid 
C3 0.215 - - - 
Purple(+) 
 
- terpenoid 
C4 0.338 - - - 
Purple(+) 
 
- terpenoid 
C5 0.400 - - - 
Purple(+) 
 
- terpenoid 
C6 1.000 - - - 
Purple(+) 
 
- terpenoid 
C7 0.765 - - Blue(+) - - phenolic 
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Table 4.4: Thin layer chromatography of chloroform extract from Aquilaria subintegra fruit in methanol solvent 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
 A1 0.45 Yellow(+) 
Yellow(+
*) 
- 
Purple(+) 
- Terpenoid 
A2  0.49 Yellow(+) 
Yellow(+) 
- 
Purple(+) 
- Terpenoid 
A3  0.69 Yellow(+) Purple(+) - Purple(++) Orange(+) Terpenoid/Alkaloid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.5: Thin layer chromatography of chloroform extract from Aquilaria subintegra fruit in chloroform solvent 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin- 
Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B1 0.06 Green(+) 
Yellow(+)
 
- 
Blue(+) 
- Terpenoid 
B2 0.18 Green(+) 
Yellow(+) 
- 
Blue(+) 
- 
Terpenoid 
B3 0.26 - 
Purple(+) 
- Purple(++) - 
Terpenoid 
B4 0.35 - 
Purple(++) 
- 
Blue(+) 
Orange(+) Terpenoid/Alkaloid 
B5 0.94 - 
Purple(+) 
- 
Blue(+) 
- 
Terpenoid 
B6 0.50 - - - 
Blue(+) 
- 
Terpenoid 
B7 0.72 - - - 
Blue(+) 
- 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.6: Thin layer chromatography of chloroform extract from Aquilaria subintegra fruit in 10% methanol in chloroform solvent 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin- 
Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C1 0.26 - Yellow(+) - Purple(+) Orange(+) Terpenoid/Alkaloid 
C2 0.41 - Yellow(+) - 
Blue(+) 
- 
Terpenoid 
C3 0.45 - Purple(+) - 
Blue(+) 
- 
Terpenoid 
C4 0.54 Yellow(+) 
Purple(++) 
- 
Blue(+) 
- 
Terpenoid 
C5 0.76 - 
Purple(+++) 
- 
Blue(+++) Orange(++) Terpenoid/Alkaloid 
C6 0.93 Green(++) 
Purple(++) 
- 
Blue(+++) Orange(+) Terpenoid/Alkaloid 
C7 0.63 - - - 
Blue(++) 
- 
Terpenoid 
C8 0.87 - - - 
Blue(+) 
- 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.7: Thin layer chromatography of methanol extract from Aquilaria subintegra leaves in chloroform solvent 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-
Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
A1 0.046 Yellow(++) - Blue(+) Blue(++) - Phenolic/terpenoid 
A2 0.153 Yellow(+) Purple(+) - - Orange(+) alkaloid 
A3 0.215 - - - 
Purple(+) 
 
- terpenoid 
A4 0.338 - - - 
Purple(+) 
 
- terpenoid 
A5 0.400 - - - 
Purple(+) 
 
- terpenoid 
A6 1.000 - - - 
Purple(+) 
 
- terpenoid 
A7 0.765 - - Blue(+) - - phenolic 
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Table 4.8: Thin layer chromatography of methanol extract from Aquilaria subintegra leaves in methanol solvent 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B1 0.15 
Yellow(+)
 
Purple(++) 
- 
Purple(+++) 
- 
Terpenoid 
B2 0.83 
Yellow(++) Purple(+++) 
- 
Purple(+++) 
- 
Terpenoid 
B3 0.96 - - - 
Purple(+) 
- 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.9: Thin layer chromatography of methanol extract from Aquilaria subintegra leaves in 10% methanol in chloroform solvent 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C1 0.125 
Yellow(+)
 
Purple(+++) 
- 
Purple(+++) 
- 
Terpenoid 
C2 0.250 
Yellow(+) Purple(+) 
- 
Purple(+) 
- 
Terpenoid 
C3 0.296 
Yellow(+) Purple(+) 
- 
Purple(+) 
- 
Terpenoid 
C4 0.343 
Yellow(+) Purple(+) 
- 
Purple(++) 
- 
Terpenoid 
C5 0.453 
- Purple(+) 
- 
Blue(+) 
- 
Terpenoid 
C6 0.500 
Yellow(+) - 
- 
Purple(+) 
Orange(+) Terpenoid/Alkaloid 
C7 0.625 
- Purple(+) 
- 
Blue(+) 
- Terpenoid 
C8 0.718 
Yellow(+) - 
Blue(+) 
Blue(++) 
- Phenol/Terpenoid 
C9 0.890 
Yellow(+) - 
- 
Purple(++) 
Orange(+) Terpenoid/Alkaloid 
C10 0.968 
Yellow(+) Purple(++) 
Blue(+) 
Purple(++) 
- Phenol/Terpenoid 
C11 0.461 
- - 
- 
Purple(+) 
- 
Terpenoid 
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Table 4.9, continued  
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 
 
 
 
 
Labelled 
compounds 
Rf value 
Observation 
Comments 
Visible light UV light 
 
Reagents 
 
Folin-Phenol Vanilin- H2SO4 Dragendroff’s 
C12 0.661 
- - 
- 
Purple(+)
 
- 
Terpenoid 
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Table 4.10: Thin layer chromatography of chloroform extract from Aquilaria subintegra leaves in chloroform solvent  
 Labelled 
compounds 
Rf value  
Observation  
comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff 
A1 0.045 
Yellow(+++)
 
- Blue(++) Blue(+++) - 
Terpenoid 
A2 0.136 
Green(++) 
- - Green(+++) - 
Terpenoid 
A3 0.242 
Yellow(+) Purple(+) 
- 
Purple(+) 
- 
Terpenoid 
A4 0.363 
Yellow(+) Purple(+) Blue(+) Purple(+) 
- 
Terpenoid 
A5 0.484 
Yellow(+) Purple(+) Blue(+) Purple(++) 
- 
Terpenoid 
A6 0.636 
Yellow(+) Purple(+) Blue(+) Purple(+) 
- 
Terpenoid 
A7 0.696 
Yellow(+) Purple(+) 
- 
Purple(++) 
- 
Terpenoid 
A8 0.893 
Yellow(+) Purple(++) 
- 
Purple(++) 
- 
Terpenoid 
A9 0.939 
Yellow(+++) 
- - 
Purple(++) 
Orange(+) Terpenoid/Alkaloid 
A10 0.090 - - - Blue(++) - Terpenoid 
A11 0.212 - - - 
Purple(++) 
- 
Terpenoid 
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Table 4.10, continued  
 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 
Labelled 
compounds 
Rf value 
Observation 
comments 
Visible light UV light 
 
Reagents 
 
Folin-
Phenol 
Vanilin- 
H2SO4 
Dragendroff 
A12 0.318 - - - 
Purple(++) 
- 
Terpenoid 
A13 0.560 - - - Blue(+) - 
Terpenoid 
A14 0.779 - - - Blue(+) - 
Terpenoid 
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Table 4.11: Thin layer chromatography of chloroform extract from Aquilaria subintegra leaves in 10% methanol in chloroform 
solvent 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-
Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B1 0.220 - Purple(+) - Purple(+) - Terpenoid 
B 2 0.441 Green(+) - Blue(+) 
Purple(++) 
- Phenol/Terpenoid 
B 3 0.500 - 
Purple(+) 
- 
Purple(+) 
- Terpenoid 
B 4 0.573 - 
Purple(+) 
Blue(++) 
Purple(+) 
- Phenol/Terpenoid 
B 5 0.676 Yellow(++) - Blue(++) 
Blue(++) 
- Phenol/Terpenoid 
B 6 0.779 Yellow(+) Purple(+) - 
Purple(++) 
- Terpenoid 
B 7 0.911 Green(+++) - Blue(++) 
Purple(+++) 
- Phenol/Terpenoid 
B8 0.073 - - - 
Purple(+) 
- 
Terpenoid 
B9 0.147 - - - 
Purple(+) 
- 
Terpenoid 
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Table 4.11, continued 
Labelled 
compounds 
Rf value 
Observation 
Comments 
Visible light UV light 
 
Reagents 
 
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B10 0.308 - - - 
Purple(++) 
- 
Terpenoid 
B11 0.367 - - - 
Purple(+) 
- Terpenoid 
B12 0.405 - - - 
- 
Orange(+) Alkaloid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.12: Thin layer chromatography of chloroform extract from Aquilaria subintegra leaves in methanol solvent 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
 C1 0.66 Yellow(++) - Blue(++) Purple(+++) - Phenol/Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.13: Thin layer chromatography of methanol extract from Aquilaria subintegra stem in chloroform solvent  
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
A1 0.076 Yellow(+) - - Blue(++) - Terpenoid 
A2 0.369 Yellow(+) - Purple(+) 
Purple(+) 
- 
Phenol/Terpenoid 
A3 0.461 - Purple(+) Purple(+) 
Purple(+) 
- 
Phenol/Terpenoid 
A4 0.184 - - - 
Purple(+) 
- 
Terpenoid 
A5 0.292 - - - 
Purple(++) 
- 
Terpenoid 
A6 0.953 - - - 
Purple(+) 
- 
Terpenoid 
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Table 4.14: Thin layer chromatography of methanol extract from Aquilaria subintegra stem in methanol solvent 
 
 
 
 
 
 
 
 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
 
 
 
 
 
 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B1 0.641 Yellow(++) Purple(+) - Purple(+) - Terpenoid 
B2 0.746 - Purple(++) Purple(++) Purple(++) - Phenol/Terpenoid 
B3 0.567 - - - Purple(+) - Terpenoid 
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Table 4.15: Thin layer chromatography of methanol extract from Aquilaria subintegra stem in 10% methanol in chloroform solvent 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C1 0.104 - Purple(+) - Purple(+) - 
Terpenoid 
C2 0.164 - Blue(++) - Purple(+) - 
Terpenoid 
C3 0.208 - Purple(+) - Purple(+) Orange(+) Terpenoid/Alkaloid 
C4 0.268 - Purple(+) - Purple(+) - 
Terpenoid 
C5 0.313 - Purple(+) - Purple(+) - 
Terpenoid 
C6 0.358 - Blue(+) - Purple(+) - 
Terpenoid 
C7 0.447 - Purple(++) - Purple(+) - 
Terpenoid 
C8 0.611 - Purple(+) - Purple(+) - 
Terpenoid 
C9 0.791 - Purple(+) - Purple(+) - 
Terpenoid 
C10 0.910 - Purple(++) - Purple(+) - 
Terpenoid 
C11 0.979 Yellow(+) - Purple(++) Purple(+) Orange(+) Phenol/Terpenoid/Alkaloid 
C12 0.298 - - - Blue(+) - 
Terpenoid 
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Table 4.15, continued  
Labelled 
compounds 
Rf value 
Observation 
Comments 
Visible light UV light 
 
Reagents 
 
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C13 0.492 - - - Purple(++) - 
Terpenoid 
C14 0.686 - - - Purple(++) - 
Terpenoid 
C15 0.850 - - - Purple(++) - 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.16: Thin layer chromatography of chloroform extract from Aquilaria subintegra stem in chloroform solvent 
Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
A1 0.068 Yellow(+) - - Purple(++) - Terpenoid 
A2 0.191 - Purple(++) - Purple(++) Orange(+) Terpenoid/Alkaloid 
A3 0.287 - - - Purple(++) - Terpenoid 
A4 0.616 - - - Blue(+) - 
Terpenoid 
A5 0.945 - - - Purple(++) - 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.17: Thin layer chromatography of chloroform extract from Aquilaria subintegra stem in methanol solvent 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
B1 0.416 Yellow(+) - - 
Purple(+) 
- Terpenoid 
B2 0.805 Yellow(+) Purple(+) Purple(+) 
Purple(+) 
- Phenol/Terpenoid 
B3 0.666 - + + 
Purple(+) 
- 
Terpenoid 
B4 0.736 - + + 
Purple(+) 
- 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Table 4.18: Thin layer chromatography of chloroform extract from Aquilaria subintegra stem in 10% methanol in chloroform solvent 
 
 
 
 
 Labelled 
compounds 
Rf value  
Observation  
Comments  
 Visible light  UV light 
  
 Reagents 
  
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C1 0.077 - Purple(+) Purple(+) Purple(+) - 
Phenol/Terpenoid 
C2 0.181 - Purple(+) Purple(+) 
Purple(+) 
- 
Phenol/Terpenoid 
C3 0.246 - Purple(+) Purple(+) 
Purple(+) 
- 
Phenol/Terpenoid 
C4 0.363 Yellow(+) 
- 
- 
Purple(+) 
- Terpenoid 
C5 0.881 - 
Purple(+) 
- 
Purple(+) - Terpenoid 
C6 0.948 Green(++) 
- 
- 
Purple(++) - Terpenoid 
C7 0.051 - - - 
Purple(++) 
- 
Terpenoid 
C8 0.142 - - Purple(+) 
Purple(++) 
- Phenol/Terpenoid 
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Table 4.18, continued 
Labelled 
compounds 
Rf value 
Observation 
Comments 
Visible light UV light 
 
Reagents 
 
Folin-Phenol 
Vanilin- 
H2SO4 
Dragendroff’s 
C9 0.285 - - - 
Blue(++) 
- 
Terpenoid 
C10 0.636 - - - 
Purple(++) 
- 
Terpenoid 
C11 0.792 - - - 
Purple(++) 
- 
Terpenoid 
 
Indication for intensity of color: +++ = strong         + = weak     ++ = medium        - = no color observed 
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Figure 4.1: HPLC/MS profile of chloroform leaves crude extracts from Aquilaria subintegra. 
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Figure 4.2: The LCMS/MS profile of Delphinidin-3-glucoside from chloroform leaves crude extract from Aquilaria subintegra 
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Figure 4.3: The LCMS/MS profile of 2(3,4-Dihydroxyphenyl)-7-hydroxy-5-benzene propanoic acid from chloroform leaves crude 
extract from Aquilaria subintegra. 
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Figure 4.4: The LCMS/MS profile of benzenepropanoic acid conjugate from chloroform leaves crude extract from Aquilaria 
subintegra  
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Figure 4.5: HPLC/MS profile of chloroform stem crude extracts from Aquilaria subintegra. 
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Figure 4.6: The LCMS/MS profile of 5.7-Dihydroxyl-4’-dimethoxyflavone from chloroform stem crude extract from Aquilaria 
subintegra 
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Figure 4.7: The LCMS/MS profile of Kaempferol 3,4,7-trimethyl from chloroform stem crude extract from Aquilaria subintegra. 
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Figure 4.8: The LCMS/MS profile of 5-Hydroxy-7,4-dimethoxyflavone  from chloroform stem crude extract from Aquilaria 
subintegra. 
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4.2 Total phenol and total flavonoids contents 
(i) Total flavonoids contents 
 
 
Figure 4.9: The total flavonoids contents of fruit, leaves and stem of Aquilaria subintegra from chloroform, methanol and  
water extract.  
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(ii) Total phenols contents 
 
 
Figure 4.10: The total phenol contents of fruit, leaves and stem of Aquilaria subintegra from chloroform, methanol and 
water extract 
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4.3 Toxicity assay 
4.3.1 Brine shrimp lethality assay (BSLA) 
 
Table 4.19: Brine Shrimp Lethality Assay 
(BSLA)  
Extract Sample 
LC50 value 
(μg/ml)±SD 
Chloroform 
Stem 3.11±0.09 
Leaves 11.64±0.19 
Fruit 68.76±0.28 
Methanol 
Stem 49.42±0.55 
Leaves 17.71±0.85 
Fruit 61.57±0.38 
Water 
Stem 32.39±0.39 
Leaves 17.58±0.26 
Fruit 61.32±0.34 
Test sample Kaempferol 9.59±0.20 
Standard Berberine 12.57±0.14 
 
 
4.3.2 Toxicity test on mice 
(i) Mortality 
No mortality figured out during study 
(ii) Physical observations 
Daily observations recorded during the study showed that test article 
administrations had no side effects on mice.  
(iii) Body weights 
There were no statistically significant differences found between 3 groups of mice 
which were orally gavage at doses of 0.1, 0.5 and 1 ml/g body weight compared with 
control group (0 ml/g body weight).    
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Figure 4.11: Mean body weights in male mice 
 
 
Figure 4.12: Mean body weights in female mice 
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4.4 AChE activity assay 
 
Figure 4.13: Percentage of AChE inhibition of chloroform leaves and stem crude extracts of Aquilaria subintegra, kaempferol and 
berberine.
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4.5 Animal study 
(i) The number of repeat entries to arms of the maze  
 
Figure 4.14: The number of repeat entries to arms of the maze (NRE) in male mice 
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Figure 4.15: The number of repeat entries to arms of the maze (NRE) in female mice  
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(ii) The number of entries to arms of maze until the first error occurs 
 
Figure 4.16: The number of entries to arms of maze until the first error occurs (NEF) in male mice 
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Figure 4.17: The number of entries to arms of maze until the first error occurs (NEF) in female mice 
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(iii) The number of repeat entries to arms of the maze without administration of valium 
 
Figure 4.18: The number of repeat entries to arms of the maze (NRE) without administration of valium in male mice  
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Figure 4.19: The number of repeat entries to arms of the maze (NRE) without administration of valium in female mice  
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(iv) The number of entries to arms of maze until the first error occurs without administration of valium 
 
Figure 4.20: The number of entries to arms of maze until the first error occurs (NEF) without administration of valium in male mice 
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Figure 4.21: The number of entries to arms of maze until the first error occurs (NEF) without administration of valium in female mice 
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CHAPTER 5 DISCUSSIONS 
 
The AChE inhibitory activity for leaves chloroform extract of Aquilaria subintegra 
(LCAS), stem chloroform extract of Aquilaria subintegra (SCAS) and kaempferol were 
80%, 93% and 85.8%, respectively (Figure 4.13). Acetylcholine (ACh) is hydrolyzed by 
AChE through a reaction between the thiocholine and DTNB, to generate the yellow anion 
of 5-thio-2-nitrobanzoic acid (Atta-ur Rahman et al., 2001). The inhibition activity of 
AChE was measured by this reaction. LCAS and SCAS displayed high inhibitory activity 
at low concentrations, which was comparable to kaempferol, whereas the inhibitory activity 
of berberine was observed at higher doses only. The LC50 of LCAS and SCAS, kaempferol 
were 3.11μg/ml, 11.64μg/ml and 9.59μg/ml respectively and there were not toxics (Table 
4.19). The results of toxicity test on mice exhibited no mortality during the study. Daily 
observations showed that administration of the articles had no side effects on mice. 
Additionally, there were no statistically significant differences between 3 groups of mice 
which were orally gavage at doses of 0.1, 0.5 and 1 ml/g body weight compared with 
control group (Figures 4.11; 4.12). These results displayed the insignificant toxicity effect 
of LCAS and SCAS, kaempferol and the standard drug. For LCAS and SCAS the total 
flavonoid contents were 414 mg QE/g dw and 645 mg QE/g dw (Figure 4.9) and the total 
phenol contents were 164 mg GAE/g dw and 210 mg GAE/g (Figure 4.10), respectively.  
The results from TLC of LCAS displayed that the existence of alkaloids and 
phenols (Tables 4.16; 4.17). Phenols cover the existence of flavonoids. Numerous studies 
broadcasted that some of the alkaloids and flavonoids have AChE inhibitor activity (Yung 
et al., 2011; Kim et al., 2004: Jung and park, 2007). Besides, TLC of SCAS exhibited the 
presence of alkaloids and phenols (Tables 4.10; 4.11). 
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The analysis of the LCAS with LCMS/MS displayed that it contain Delphinidin-3-
glucoside (Figure 4.2), 2(3,4-Dihydroxyphenyl)-7-hydroxy-5-benzene propanoic acid 
(Figure 4.3) and benzenepropanoic acid conjugate (Figure 4.4).  The same analysis on 
SCAS, indicated the presence of 5-Hydroxy-7,4-dimethoxyflavone (Figure 4.6), 
kaempferol 3,4,7-trimethyl ether (Figure 4.7) and 5.7-Dihydroxyl-4’-dimethoxyflavone 
(Figure 4.8). 
Dong et al. (2005) investigated two AChE inhibitors physostigmine and donepezil 
on memory related behaviors of mice. They suggested that AChE inhibitors could improve 
memory deficits in mice. Ikarashi et al. (2004) examined mice memory disturbance by 
measuring AChE concentrations in their brains. They found out that memory impairment in 
cholinergic system of the mice is due to Aβ accumulation which happens when AChE 
increased. Figueiró et al. (2010) extracted AChE inhibitors from Ptychopetalum olacoides 
and orally administrate these compounds to the mice. They improved meaningful AChE 
inhibitor activity of these extracts for treating neurodegenerative conditions which is useful 
for AD treatment. In 2011, Foti and colleagues considered that the Radial Arm Maze 
(RAM) can be analyzed via movement most aspects of the spatial function, as the analytical 
memory and the appropriate working memory. RAM is a practicable memory testing for 
displaying the effect of drugs. ICR mice (male and female) were used to evaluate the 
effectiveness of LCAS and SCAS. The working memory was assessed by measuring the 
number of repeat entries to arms of the maze already visited (NRE). For instance if NRE is 
2 it means that the mouse eats all 8 pellet with 2 times comes back to the arms of the maze 
which is the pellet was eaten before (2 errors).  Together with the kaempferol and berbrine 
the results of testing memories with RAM displayed that the lowest number of NRE was 
related to the control group (Figures 4.14; 4.15).  
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Valium possesses sedative intensifies the effect of the neurotransmitter Gamma-
Aminobutyric Acid (GABA) leading to Central Nervous System (CNS) depression, it 
utilized to cause memory impairment on mice. During a study in 2012 taking the valium 
causes side effects in 18583 people. Among them, in 23 people (69.57% in females and 
30.43% in males) taking the valium leads to AD (http://www.ehealthme.com). Regular 
valium taking causes 77.27% AD among the people with more than 60 years of age and 
69.57% in females. As figure 4.14 and 4.15 noticed repeated entries to arms of the maze in 
control group were 1.9 in male and 1.6 in female mice. The NRE was significantly 
increased when the mice were administrated with valium at 11.2 and 13.1 in male and 
female mice, respectively (Figures 4.14; 4.15).  
Then, the plant extracts and kaempferol were administrated to the valium-treated 
mice.  Lowest NRE was observed in mice which were administrated with kaempferol 3.3 
and 4.1 in female and male nice, respectively (Figures 4.14; 4.15). In 2008, Serhan and 
colleagues reports that chronic inflammation has a detrimental effect on AD. Besides that, 
in 2010 Kim and colleagues broadcasted that administration of kaempferol in ICR mice 
significantly inversed the effect of Aβ. They utilized the Y-maze test to prove the ability of 
kaempferol to meliorate the memory impairment in mice caused by Aβ. One of the 
outstanding features perceived in AD patients is deficiency of ACh, a neurotransmitter in 
the synapses of the cerebral cortex. AChE is ACh hydrolyzing enzyme, which can 
promulgate the assembly of Aβ into fibrils. In 2006, Tabet suggested that AChE inhibitors 
could be effective in treatment of AD by increasing the acetylcholine mediated neuron to 
neuron transmission. García-Ayllón and colleagues (2011) have reported that AChE is due 
to decreasing in acetylcholine has important role in AD treatment. Silvestrelli et al. (2006) 
broadcasted that the cholinergic hypothesis of AD has act as a powerful encouragement to 
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pharmacotherapeutic strategies of AD, which focus on improving the cholinergic 
inadequacy and potentiating residual activity in affected neuronal circuits by reforming 
cholinergic transmission. For amplifying cholinergic activity in brain by maintain ACh 
level, AChE inhibitors has been widely pursued as the most powerful approach. Loizzo et 
al. (2008) discussed that in AD patients, AChE inhibitors could minimize the formation of 
neurotoxic fibrils and clumping of Aβ, hence AChE inhibitors might be useful in treatment 
cognitive symptoms of AD (Kalauni et al., 2002; Atta-ur-Rahman et al., 2004). Since 
AChE inhibitors have the anti-inflammatory activity they could protect neuron cells from 
the injuries caused by free radicals and Aβ. The significant activity of kaempferol as a 
natural AChE inhibitor (Figure 4.13) confirms its potential to be applied as an alternative 
drug in the treatment of AD.  
Berberine is an alkaloid with anti-inflammatory activity and is utilized as a drug for 
treatment of AD. Some investigations suggested that berberine may have AChE inhibitory 
effects and it could be useful for the prevention of AD as well (Xiang et al., 2009 and 
Huang et al., 2009). The NRE for the berberine administrated mice was 4.4 and 4.1, for 
male and female mice, respectively (Figures 4.14; 4.15). Results obtained from the mice 
administrated with berberine, LCAS and SCAS, were approximately the same (Figures 
4.14; 4.15). The decline in NRE might be due to the presence of delphinidin in LCAS and 
kaempferol in SCAS, which is a flavonoid with anti-inflammatory effect and support the 
finding made by Takasawa et al. (2010). In 2012, Inoue and colleagues found that 
delphinidin declined the amount of epigallocatechin-3-gallate (EGGG), which causes 
cytotoxicity and enhanced the endoplasmic reticulum (ER) stress.  The ER stress, which is 
one of the AD pathogenesis effects on Aβ generation (Kudo et al., 2006). The group of 
mice, administrated with LCAS, had higher NRE compare to SCAS administrated one. The 
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NRE in mice which administrated LCAS was 8.4 and 7.9 in male and female mice, 
respectively (Figures 4.14; 4.15). The group of mice which administrated SCAS had 6.6 
and 6.1 in male and female (Figures 4.14; 4.15). The results obtained from the group of 
mice administrated with valium indicated a remarkable increase in NRE. Contrarily, LCAS, 
SCAS and kaempferol-treated animals exhibited a drastic decrease in NRE (Figures 4.14; 
4.15).  
The ANOVA results demonstrated the significant effects of LCAS and SCAS on 
the memory of mice (Appendix A.1; A.2). The findings of the RAM clearly showed higher 
effects of LCAS, SCAS and kaempferol in female mice compare with the males. Likewise, 
there was a decreasing trend in NRE. After administration of valium, no statistically 
significant effects were perceived in NRE between the male mice administrated with LCAS 
plus SCAS, keampferol and berberine (Appendix A.5). On the other hand, the difference in 
NRE administrated with kaempferol compared was severely significant in female mice to 
the ones administrated with LCAS plus SCAS and berberine. It displayed that LCAS plus 
SCAS, kaempferol and berberine were more effective than LCAS and SCAS in male and 
female mice. Kaempferol was the most effective treatment in the female mice and 
significantly declined NRE (Appendix A.6).   
Comparison of the ANOVA results of the NRE, between male and female mice, 
demonstrates that the kaempferol has been significantly more effective in females 
(Appendix A.7). It exhibited that female mice got a better response to the AChE inhibitors 
than males.  Spampinato et al. (2011) focused on the analysis of Magnetic Resonance 
Imaging (MRI) images which displayed that AD tends to harm women in advance, however 
it is more aggressive in men.  
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In another measurement for memory testing on mice the number of entries until the 
first error occurs (NEF), was counted. As it is observable in Figure 4.16 and 4.17, control 
group had the highest NEF 6.7 and 7.1 in male and female mice, respectively. The lowest 
NEF was perceived when the mice were administrated with valium (1.94 in male and 1.68 
in female mice). The mice administrated with kaempferol had 5.4 and 5.9 entries in male 
and female mice, respectively. The group of mice administrated berberine had 4.6 and 5.2 
entries in male and female mice, respectively. NEF significantly decreased when the mice 
was treated with valium (Appendix A.3; A.4). The group of mice administrated with 
kaempferol had the highest NEF. NEF in the mice administrated with LCAS plus SCAS 
was more than 2 other groups of mice administrated with LCAS and SCAS. The lowest 
NEF was noticed in the group of mice administrated with LCAS. In group of mice 
administrated with LCAS plus SCAS, NEF were 4.1 and 4.3 in male and females, 
respectively (Figures 4.16; 4.17). The lowest NEF was noticed in the group of mice 
administrated with LCAS, 2.9 and 3.1 in male and female mice, respectively (Figures 4.16; 
4.17). The group of mice administrated with SCAS had 3.4 and 3.8 NEF in male and 
female, respectively (Figures 4.16; 4.17). 
The results obtained from the group of mice, treated with LCAS, SCAS and 
kaempferol, without administration of valium, indicated statistically insignificant effects in 
NRE and NEF in all groups, male and female (Figures 4.18; 4.19; 4.20; 4.21) . It illustrated 
that LCAS, SCAS and kaempferol were effective after administration of valium to the 
mice. Administration of LCAS, SCAS and kaempferol after treating with valium, caused a 
marked reduction in NRE. This finding indicates that without impairment of mice memory 
LCAS, SCAS and kaempferol exhibited insignificant effects. 
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CHAPTER 6 CONCLUSION 
 
The results from TLC of leaves and stem chloroform extract of A.subintegra 
displayed that the existence of alkaloids and phenols. The analysis of the stem chloroform 
extract with LCMS/MS displayed that it contain kaempferol. A flavonoid kaempferol has 
the AChE inhibitor activity of 85.8% and LC50 = 9.59µg/ml. Leaves and stem chloroform 
extract significantly reduced the number of repeated entries to the arms of the maze in male 
and female ICR mice with impaired memory by valium in Radial Arm Maze (RAM). The 
decline in the number of repeated entries to the arms of the maze might be due to the 
presence of kaempferol. Furthermore, the highest number of entries until the first error 
occurs was perceived in kaempferol administrated mice. The kaempferol could improve 
memory impairment in mice. It can be a potent natural AChE inhibitor and could be used as 
an alternative to the chemical drug instead of berberine for the treatment of Alzheimer’s 
disease. However, there is a definite requirement for further mechanistic investigations to 
confirm and validate the effects for the treatment of Alzheimer’s disease. 
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APPENDIX  
Appendix A.1: The ANOVA results of Number of repeated entries to arms of maze (NRE) in male mice 
 
 
 
 
 
 
Appendix A.2: The ANOVA results of Number of repeated entries to arms of maze (NRE) in female mice 
 
 
 
 
 
 
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
q Significant? P < 
0.05? 
Summary 95% CI of diff 
valium vs stem 4.11 58.76 Yes *** 3.877 to 4.343 
valium vs leaves 6.625 94.71 Yes *** 6.392 to 6.858 
valium vs stem+leaves 8.805 125.9 Yes *** 8.572 to 9.038 
valium vs kaempferol 9 128.7 Yes *** 8.767 to 9.233 
valium vs berberine 8.72 124.7 Yes *** 8.487 to 8.953 
valium vs control 11.23 160.5 Yes *** 11.00 to 11.46 
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? P < 
0.05? 
Summary 95% CI of diff 
valium vs stem 3.025 54.84 Yes *** 2.841 to 3.209 
valium vs leaves 6.895 125 Yes *** 6.711 to 7.079 
valium vs stem+leaves 8.875 160.9 Yes *** 8.691 to 9.059 
valium vs kaempferol 9.675 175.4 Yes *** 9.491 to 9.859 
valium vs berberine 9.08 164.6 Yes *** 8.896 to 9.264 
valium vs control 11.38 206.2 Yes *** 11.19 to 11.56 
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Appendix A.3: The ANOVA results of the number of entries until the first error occurs (NEF) in male mice 
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
control vs valium 4.795 224.3 Yes *** 4.722 to 4.868 
control vs stem 3.835 179.4 Yes *** 3.762 to 3.908 
control vs leaves 3.305 154.6 Yes *** 3.232 to 3.378 
control vs stem+leaves 2.700 126.3 Yes *** 2.627 to 2.773 
control vs kaempferol 1.300 60.80 Yes *** 1.227 to 1.373 
control vs berberine 2.110 98.69 Yes *** 2.037 to 2.183 
 
 
Appendix A.4: The ANOVA results of the number of entries until the first error occurs (NEF) in female mice 
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
control vs valium 5.425 196.2 Yes *** 5.333 to 5.517 
control vs stem 4.000 144.7 Yes *** 3.908 to 4.092 
control vs leaves 3.310 119.7 Yes *** 3.218 to 3.402 
control vs stem+leaves 2.825 102.2 Yes *** 2.733 to 2.917 
control vs kaempferol 1.210 43.77 Yes *** 1.118 to 1.302 
control vs berberine 1.875 67.82 Yes *** 1.783 to 1.967 
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Appendix A.5: The ANOVA results of comparison of LCAS plus SCAS, kaempferol and berberine in male mice   
Bonferroni's Multiple 
Comparison Test 
Mean 
Diff. 
t Significant? P < 
0.05? 
Summary 95% CI of diff 
stem+leaves vs kaempferol 0.195 2.788 No ns -0.1293 to 0.5193 
stem+leaves vs berberine -0.085 1.215 No ns -0.4093 to 0.2393 
kaempferol vs berberine -0.28 4.003 No ns -0.6043 to 0.04428 
 
 
 
 Appendix A.6: The ANOVA results of comparison of LCAS plus SCAS, kaempferol and berberine in female mice   
 
 
 
 
 
 
 
 
Bonferroni's Multiple 
Comparison Test 
Mean Diff. t Significant? P < 
0.05? 
Summary 95% CI of diff 
stem+leaves vs kaempferol 0.8 14.5 Yes *** 0.5443 to 1.056 
stem+leaves vs berberine 0.205 3.716 No ns -0.05073 to 0.4607 
kaempferol vs berberine -0.595 10.79 Yes *** -0.8507 to -0.3393 
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Appendix A.7: The ANOVA results of comparison of LCAS plus SCAS, kaempferol and berberine in male and female mice 
Bonferroni's Multiple 
Comparison Test 
Mean Diff. t Significant? P < 0.05? Summary 95% CI of diff 
berberine (male) vs berberine 
(female) 
0.54 13.68 Yes *** 0.3545 to 0.7255 
kaempferol (male) vs 
kaempferol (female) 
0.855 21.66 Yes *** 0.6695 to 1.040 
stem+leaves (male) vs 
stem+leaves (female) 
0.25 6.333 Yes * 0.06455 to 0.4355 
 
